Pharmacy Times October 15, 2024
Alana Hippensteele, Managing Editor

Key Takeaways

  • The FDA struggles with regulating AI/ML devices, often underestimating their prevalence and impact in medical devices.
  • Continuous glucose monitors, despite AI/ML integration, follow traditional approval pathways, bypassing AI-specific scrutiny.
  • Ethical concerns arise from AI biases, as studies reveal racial and gender disparities in medical diagnoses.
  • Many AI/ML devices lack transparency and validation, posing challenges for regulatory oversight and public trust.

The FDA faces a multitude of challenges in regulating artificial intelligence (AI) and machine learning (ML) medical devices.

There are a lot of parallels with how the FDA manages the review of devices and drugs, explained Omar Badawi, PharmD, MPH, FCCM, during a presentation at the 2024 American College of Clinical Pharmacy (ACCP) Annual Meeting. However,...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), FDA, Govt Agencies, Medical Devices, Technology
FDA warns GLP-1 compounder over safety rules
GLP-1 drug approvals: A breakdown
Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Certainty vs. speed: How do patients feel about the tradeoff for new cancer drugs?

Share This Article